Llombart-Cussac et al. have attempted to modify therapy according to the intrinsic features of the tumor, determining the value of intrinsic molecular subtypes in predicting pCR in patients with HER2-positive BC following neoadjuvant dual blockade with trastuzumab and lapatinib in the absence of chemotherapy in the PAMELA trial [102]. The gene discussed is ERBB2; the disease is breast cancer.